Kornimate/medical-research-clean huggingface dataset:
comparison of lasers in the treatment of scars

Conditions: Scar

Summary: the purpose of this study is to compare the 1550-nm non-ablative fraxel laser (referred to as fraxel laser in this application) to the ablative 10,600-nm carbon dioxide fractional laser (referred to as co2 laser in this application) to determine if one is superior to the other in improving the appearance of scars over a series of three treatments. in addition, the investigators hope to identify a more cost-effective method to improve the appearance of scars caused by surgery or trauma.

this study will be accomplished through a controlled split-scar study design whereby half of the scar will be treated with the fraxel laser and the other half of the scar will be treated with the co2 laser. this study is a blinded, prospective comparative, split-scar study whereby 100 participants will be recruited, enrolled and followed for a period of 9 months. the study population will include male and female participants, age 18 and over with scars secondary to surgery or trauma on any part of the body. the study will recruit participants with light colored skin, fitzpatrick type i-iv, because colored skin has a significantly higher risk of keloid scarring. the scar must measure a minimum of 4 cm in length to accommodate for the split-scar treatment. the participants will undergo laser treatments on visit 1, visit 2 and visit 3 and each visit will be 4 weeks apart. the participants will return for evaluation and follow-up 3 months and 6 months following the last laser treatment. at each visit, photographs will be taken using identical camera settings, lighting and participant positioning. evaluation of the scars will be completed by the participants and by blinded dermatology physicians. participants will use a complete visual analogue scale at each visit, the patient and observer scar assessment scale (posas) and a satisfaction score.

Eligibility criteria:
inclusion criteria: 1. age 18 or older. 2. fitzpatrick skin type i-iv. 3. scars secondary to surgery or trauma. 4. scar length minimum 4 cm in length. exclusion criteria: 1. scars less than 6 weeks old. 2. history of keloid scarring. 3. use of isotretinoin currently or within 3 months of enrollment 4. use of photosensitive medication currently or within 3 months of enrollment. 5. pregnancy -
establishment of online registration platform for unruptured intracranial aneurysms based on regional medical centers in china and population follow-up study (phase ⅱ)

Conditions: Intracranial Aneurysm

Summary: intracranial aneurysm is the main cause of subarachnoid hemorrhage, and the incidence of subarachnoid hemorrhage in chinese population is about 5%. the intervention of unruptured intracranial aneurysms is controversial because of its great harm after natural rupture and bleeding, and about a quarter of patients still have poor prognosis through existing invasive treatment methods. how to accurately determine the instability risk of unruptured intracranial aneurysms is the key to resolve this controversy. in previous studies, the stability of intracranial aneurysms involves many characteristics, and the sample size is small. most of them are retrospective studies and studies on the status after change (rupture/growth). therefore, the relevant risk factors are not clear at present, and there is still a lack of reliable prediction model. based on the above facts, this study proposed based on the national hundred regional medical institutions set up the network registration platform of unruptured intracranial aneurysms, real time and openness of internet, through the way of case resource sharing build unruptured intracranial aneurysm queue, collecting clinical characteristics, imaging features, hemodynamic detection of biological samples and the results of the analysis data, and observe them for two years. the artificial intelligence platform of tonglian medical health was used to integrate and analyze and learn all the data, and then the risk factors related to the stability of intracranial aneurysms within two years were obtained, and the stability prediction model of unruptured intracranial aneurysms was constructed. this study will build the largest network registration platform and population follow-up cohort of unruptured intracranial aneurysms in china, and put forward a prediction model for the stability of unruptured intracranial aneurysms by integrating the multi-dimensional factors of intracranial aneurysms, so as to provide a powerful auxiliary judgment tool for the clinical decision-making of this disease.


Eligibility criteria:
inclusion criteria: 1. 18-75 years old; 2. at least one unruptured intracranial aneurysm was found by cta; 3. no relevant symptoms, receiving non-operative and conservative observation treatment; 4. signing the informed consent. exclusion criteria: 1. other cerebrovascular structural lesions (such as cerebrovascular malformation and arteriovenous fistula) or craniocerebral tumors; 2. fusiform or dissecting aneurysms; 3. traumatic, mycotic and atrial myxoma associated aneurysms; 4. suffering from systemic connective tissue diseases, such as polycystic kidney disease; 5. expectant survival of no more than 3 years due to other diseases or poor general conditions; 6. patients refuse to follow up or cannot communicate with them due to mental diseases; 7. pregnant women or participating in other aneurysm related studies.

Keywords: intracranial aneurysm artificial intelligence
the effect of cold application on pain level, edema and drainage amount

Conditions: Cold Therapy; Pain, Postoperative

Summary: in this study, we aimed to investigate the effect of cold application applied for 20 minutes every hour for 8 hours on the first day, second and third days after total hip arthroplasty with gel pads, on the pain level, edema and drainage amount of total hip arthroplasty patients. the main question\[s\]it aims to answer are: * is there a difference between the pain levels of patients in the control and cold application arms? * is there a difference between the knee edema of patients in the control and cold application arms? * is there a difference between the amount of drainage of patients in the control and cold application arms? this study was planned as a prospective, parallel, two-arm (1:1) randomized controlled trial (rct).

* when the patient arrives at the service after tka, cold application will begin with gel pads at 0 ºc and continue for eight hours. after tka, cold application will continue for 20 minutes every hour between 08.00-16.00 on the 1st and 2nd day. * after tka, pain intensity will be evaluated and at the 6th, 24th and 48th hours. * knee circumference measurements for knee edema will be made before tka and at the 24th and 48th hours after tka. * after being taken to bed after tka, the amount of drainage will be measured at the 1st, 6th and 24th hours. * in the first 24 hours and 24-48 hours after tka. analgesic consumption between hours will be recorded. * knee temperature will be measured before and after each cold application. * knee temperature will be measured before and after each cold application. measurements of the control group will be made at the specified times in the cold application group. cold application will not be applied to the control group.

Eligibility criteria:
inclusion criteria: * 18 years and above, * able to communicate verbally and in writing, * turkish speaking, * tka applied for the first time, * unilateral total knee arthroplasty applied, * spinal anesthesia applied, * having a hemovac drainage catheter, * without peripheral vascular disease, exclusion criteria: * revision total knee arthroplasty applied, * bilateraltotal knee arthroplasty applied, * those who use alcohol and substances, * tka was performed for a reason other than knee osteoarthritis, * general anesthesia applied,

Keywords: cold therapy pain patient knee arthroplasty
spironolactone and dexamethasone in patients hospitalized with covid-19

Conditions: Coronavirus Infection; Pneumonia, Viral

Summary: the severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is a rapidly spreading infection of the respiratory tract. most infected patients have either asymptomatic disease or mild symptoms. however, a proportion of patients, especially elderly men or patients with comorbidities, are at risk of developing acute respiratory distress syndrome (ards). ards, alongside clotting abnormalities, is known to be a major contributor to sars-cov-2-related mortality and admission to intensive care units, with evidenced effective preventative treatment options lacking. in this study, the investigators test a novel hypothesis that the use of a combination of spironolactone and dexamethasone at low doses will improve the clinical progression of the infection evaluated by the 6-point ordinal scale in patients with moderate and severe disease by blocking exocytosis of the weibel-palade bodies from endothelial cells.


Eligibility criteria:
inclusion criteria: * age 18 years or above; * signed informed consent; * pcr-confirmed diagnosis of sars-cov-2 infection * presenting with moderate-to-severe disease (scores 4-6 on who ordinal scale) exclusion criteria: * women of childbearing age without a negative urine pregnancy test, currently pregnant or breastfeeding women; * severe heart failure (nyha4), severe renal failure (egfr \ 5 norms), severe anemia (haemoglobin \< 30 g/l) * participating in another clinical trial * severe electrolyte imbalance (hyperkalemia \> 5.0 mmol/l, hyponatremia \< 120 mmol/l) * hypersensitivity or contraindications to the study drugs (spironolactone and dexamethasone) * renal dialysis * severe uncontrolled diabetes mellitus * patient receiving one of the following medications that cannot be substituted over the trial duration: ace inhibitors, amiloride, eplerenone, cortisone acetate, potassium canrenoate, triamterene
exercise and noninvasive ventilation in heart failure patients

Conditions: Heart Failure

Summary: introduction: dyspnea and fatigue determine exercise intolerance in heart failure (hf) subjects, hampering performance in activities of daily living. in this context, noninvasive ventilation (niv) has been used to minimize such impairment, increasing functional capacity aim: to evaluate the impact of niv on exercise performance in hf individuals. methods: a randomized crossover clinical trial with allocation concealment consisted of two experimental phases: niv and control, 7 days apart of each other. during niv phase, 30 minutes of bi-level ventilation was performed. any type of ventilator support was offered during control phase. functional capacity was assessed by cardiopulmonary exercise test on a treadmill.


Eligibility criteria:
inclusion criteria: * both sexes, 18-60 years * body mass index (bmi) \<30 kg/m2 * functional class ii-iii according to the new york heart association * of the echocardiogram últiimos 6 months showing ejection fraction (lvef) ≤ 45% - echocardiogram of six months showing cardiac hypertrophy (left ventricular diastolic diameter (lvdd)\> 55mm * diameter systolic left ventricular (lvsd)\> 45mm ) * optimized from the point of view of drug and (6) clinical stability exclusion criteria: * (1) unstable angina, myocardial infarction or heart surgery three months before the beginning of the research (2) chronic orthopedic, infectious or metabolic diseases (3) fev1/fvc \<70% predicted characterizing obstructive respiratory disorder; (4) active smokers (5) limitation on the use of niv: claustrophobia, inability to remain with their mouths closed, abdominal distention, hemodynamic instability, heart rate (hr) \<60 bpm, recent trauma, nausea and vomiting face
fast discharge after acute myocardial infarction discharge mi

Conditions: Acute Myocardial Infarction (AMI)

Summary: to evaluate the hypothesis that a fast discharge strategy (discharge at 24 \[± 12\] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (72 \[± 24\] hours) with respect to the risk of major adverse cardiovascular events (mace) at 12 months.

the goal of this randomized, multicenter trial is to assess the safety of a fast discharge strategy following acute myocardial infarction as compared to standard of care. the trial will evaluate the hypothesis that a fast discharge strategy (discharge at 24 \[± 12\] hours) following invasive management of acute myocardial infarction is non-inferior to standard of care (discharge at 72 \[± 24\] hours) with respect to the risk of major adverse cardiovascular events at 12 months.

Eligibility criteria:
inclusion criteria: * uncomplicated acute myocardial infarction (nstemi and stemi) diagnosed according to the 2023 acute coronary syndrome guidelines of the esc * age ≥ 18 years at time of consent * invasive management strategy and in case of pci successful intervention of the culprit lesion defined by post-interventional timi 3 flow * absence of pci-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection/occlusion or emboli) * ability to understand and willingness to sign and date written informed consent exclusion criteria: * myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest) * malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (\< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree atrioventricular block) after pci * ongoing hemodynamic instability (systolic blood pressure \<90 mmhg, elevated lactate concentrations, need for inotropes or vasopressors) * ongoing respiratory instability defined by killip class \>i (rales, pulmonary edema) * ongoing quantitative disorders of consciousness (somnolence, sopor, coma) * pregnancy * immobility/limited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team

Keywords: myocardial infarction stemi nstemi discharge randomized
dose escalation study of liposomal paclitaxel with/without capecitabine in patients with advanced gastric carcinoma

Conditions: Gastric Carcinoma

Summary: the purpose of this study is to investigate the maximum tolerated dose and pharmacokinetics of liposomal paclitaxel with/without capecitabine in chinese cancer patients with advanced gastric carcinoma.

the maximum tolerated dose (mtd) and pharmacokinetics of a new formulation of taxane (liposomal paclitaxel) have never been studied in chinese cancer patients, either alone or with capecitabine .this clinical trial is designed to find out the mtd and pharmacokinetics of liposomal paclitaxel with a beginning dose of 175mg/m2 with/without capecitabine in chinese patients with advanced gastric carcinoma.

Eligibility criteria:
inclusion criteria: * histologically verified gastric carcinoma of advanced stages which is unsuitable for surgery; * no prior systemic chemotherapy with taxane at least 6 months before the recruitment; * at least one measurable tumor according to recist standard, with at least one diameter ≥20mm assessed by traditional imaging technique or mri, or with a diameter twice of the thickness of scan layer (or ≥10-16mm) under spiral ct; eastern cooperative oncology group (ecog) performance status (ps) 0-1; * patients who are expected to live at least 3 months; * obtaining informed consent; exclusion criteria: * receiving other chemotherapy or radiotherapy during the administration; * symptomatic metastatic brain tumor; * allergy to any study medication; * pregnancy or breast feeding; * severe heart diseases; * uncontrolled mental diseases; * abnormal liver and renal functions, which are measured by ast/alt and bun/cr; * neutrophils（anc）\<2000/μl;platelets\<100，000/μl;hemoglobin（hb）\<9.0 g/dl;

Keywords: liposomal paclitaxel maximum tolerated dose pharmacokinetics gastric carcinoma
uc-mscs gel treatment difficult healing of skin ulcers

Conditions: Difficult to Healing of Skin Ulcers

Summary: this study for a six-month trials, randomized, open, and parallel comparison before and after its own, stage test includes screening stage, treatment period and follow-up period. in accordance with chronic wound criteria for the patient, by producing the principle of random number, were randomly divided into uc-mscs gel group or gel group, the researchers according to the situation of wound healing time and decided to use the secondary treatment, to observe the clinical efficacy and safety.


Eligibility criteria:
inclusion criteria: * older than 17 year old male or female (pregnancy); * has the ability to care for, has the ability to self signed informed consent, 7 to 17 years of age must be signed by the guardian informed consent; * the process of psychological stability, can finish the tes exclusion criteria: * allergic constitution, or known allergic to pork or beef source products, gao min physique person; * the wound is more than 10 cm by 10 cm; * people with mental illness, drug abusers and or other items; * 1 month used or are using the sugar metabolism of drugs, such as corticosteroids, thiazide diuretics, tricyclic antidepressants, etc; * 3 month participated in other similar test; * serious infectious disease not controller; * with surgery, such as severe trauma stress situation; * always had a history of tumor; * clinical researchers or for other reasons can't cooperate with the doctors, and other information is not suitable for clinical study of patients.
the effect methylphenidate hydrochloride on pain and auditory sensitivity in healthy subjects

Conditions: Pharmacological Action (PA)

Summary: 1. to examine whether ritalin has analgesic properties in healthy subjects. 2. to examine if ritalin analgesic effect is a pain specific phenomenon or a part of a broader, non-specific effect on high mental functions.


Eligibility criteria:
inclusion criteria: * male subjects between the ages of 20 to 40 * healthy subjects without known disease and without any chronic pain * subjects without known cognitive problems, which can understand the research and its goals * subjects who are not taking any medications * subjects without hearing problems * subjects without attention deficit disorder (adhd) problems exclusion criteria: * subjects who are known to suffer from any disease or any chronic pain * subjects taking psychotropic drugs (except ritalin) or any analgesics * subjects who have any contradictions for ritalin administration * subjects with suspected cognitive disability

Keywords: ritalin methylphenidate hydrochloride experimental pain
effects of asc secretome on human osteochondral explants

Conditions: Osteoarthritis

Summary: since the need of finding effective disease-modifying anti-osteoarthritis (oa) treatments is still unmet, with this study the investigators aim to gather further evidences of the therapeutic potential of mesenchymal stem/stromal cell (msc) secretome in order to pave the way to its future use as a cell-free biological product. in detail, the investigators predict to validate the promising results obtained in vitro, ex vivo on osteochondral explants, an oa model more representative of the physiological situation.


Eligibility criteria:
inclusion criteria: * males and females * age≥18 years old * patients hospitalized in irccs (istituto di ricovero e cura a carattere scientifico) istituto ortopedico galeazzi, undergoing arthroplasty exclusion criteria: * age\<18 years old * patients unable to sign the informed consent * positivity to serological test (hiv-human immunodeficiency virus, hcv -hepatitis c virus, hbv -hepatitis b virus and tpha -treponema pallidum hemagglutination assay)

Keywords: mesenchymal stem/stromal cells conditioned medium extracellular vesicles asc
night owl metabolism

Conditions: PreDiabetes; Overweight; Impaired Glucose Tolerance

Summary: the proposed study uses a novel and rigorous randomized cross-over study design in youth (17-23y) with late and non-late chronotype (n=35 per group) to assess the glycemic effect of "aligning" an oral glucose tolerance test (ogtt) or first-meal of day to a subject's chronotype. both groups will undergo 2 ogtts (aligned and mis-aligned with chronotype) to compare glucose tolerance and insulin sensitivity within-subject (primary outcome) and between groups (aim 1). then, youth will also undergo two standardized meals (aligned and mis-aligned with chronotype) while wearing continuous glucose monitoring to compare post-prandial glucose excursions within-subject and between groups (aim 2). a pilot exploratory aim 3 (n=12 per group) will investigate delayed melatonin patterns under dim-light as a potential pathophysiologic mechanism behind abnormal glucose tolerance in youth with late chronotype on morning ogtts.


Eligibility criteria:
inclusion criteria: * overweight similar to (bmi ≥ 85th percentile but \<95th percentile for age and sex per centers for disease control and prevention growth curves (as centers for disease control and prevention growth curves contain ages ≤ 20y; if ages 21-23 years, the bmi ≥ 85th and \<95th percentile equivalents for a 20-year-old will be used)) * post-pubertal * normal sleep duration (avg. \>7 hours of sleep per night) * social jetlag (difference between weekend and weekday sleep) of \< 2 hours. exclusion criteria: * known diabetes, sleep disorders, major organ system illness, pregnancy, or genetic syndrome * medication use known to affect insulin sensitivity, glucose tolerance, or circadian rhythm * screening high risk for obstructive sleep apnea * night shift work.

Keywords: chronotype sleep